34 results about "Cancer Cellularity" patented technology

The invention discloses a method for evaluating an anti-cancer drug inhibiting the aggregation of membrane protein receptors. The method comprises the following steps of: (1) conveying genes of target membrane protein receptors to an excised cancer cell, and marking the genes of the target membrane protein receptors by fluorescent protein to obtain a reconstructed cancer cell; (2) hatching the reconstructed cancer cell and a substance to be evaluated, then hatching by adding ligands of the target membrane protein receptors after the last hatching is finished, and then fixing the reconstructed cancer cell by adding a PBS (Phosphate Buffered Saline) solution of paraformaldehyde to obtain a cell sample I to be detected; and (3) carrying out fluorescence imaging on the unimolecule of the cell sample I to be detected to obtain a cell image and furthermore obtain bleaching steps of each fluorescent spot, and analyzing the image and counting the bleaching steps of the fluorescent spot to judge whether the substance to be evaluated plays an inhibition role in the aggregation of the membrane protein receptors or not. The method has the advantages of simpleness and convenience for operation, short evaluation period and low expense and can be used for evaluating various drugs inhibiting the aggregation of membrane protein receptors.

The invention relates to the technical field of biomedicines, in particular to an NKT (Natural Killer T) cell preparation prepared by sensitization by using tumor cells and simulating factors and a preparation method of the NKT cell preparation. The NKT cell preparation is high in killing activity and can effectively kill remaining cancer cells, eliminate recurrence and metastasis factors, increase the curability, prolong the survival time of patients and improve the life quality by applying an immunotherapy. In the preparation process of the preparation, NKT cells are jointly cultured by adopting IL-2, IL-15 and IL-21 and sensitized by adopting the tumor cells and the stimulating factors, so that the expansion effects of the NKT cells are enhanced, and the killing activity of the NKT cell preparation is also greatly enhanced.

At present, the cancer treatment methods include the operative treatment, the radioactive treatment and the chemical treatment. Great side effects are brought to a patient during treatment with the radioactive treatment and the chemical treatment. According to the methods, huge injuries to normal cells are generated while the cancer cell development is choked. According to a whole-body tepidity cancer rehabilitation method, the in vivo temperature rapidly rises in a short time to enable the normal cells to be most active and to enable cancer cells to be difficult to survive, so that the function of improving autoimmunity is achieved, and the human body returns to the immunity level of a normal person.

Identification and evaluation of a set of first-in-class potent inhibitors targeting a new cancer target, Grb2-associated binder˜1 (GAB1), which integrates signals from different signaling pathways and is frequently over-expressed in cancer ceils. Intensive computational modeling is utilized to understand the structure of the GAB1 pleckstrin homology (PH) domain and screened five million compounds. Upon biological evaluation, several inhibitors were found that induced large conformational changes of the target structure exhibited strong selective binding to GAB1 PH domain. Particularly, these inhibitors demonstrated potent and tumor-specific cytotoxicity in breast cancer cells. This targeting GAB1 signaling may be used for cancer therapy, especially for triple negative breast cancer patients.

Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.

Acyclic nucleoside analogs such as acyclovir, ganciclovir, penciclovir and the corresponding pro-drugs, i.e., valacyclovir, valganciclovir and famciclovir, respectively have been identified as inhibitors or antagonists of both telomerase (encoded by TERT) and reverse transcriptase encoded by L-1 (LINE-1) RT, and as useful for treating or preventing cancers induced or mediated by the two enzymes. Method of treating or preventing such cancers in patients involves administration of a therapeutically effective amount of a composition having an inhibitor or antagonist of the reverse transcriptases in cells of the patients. The inhibitor or antagonist blocks lengthening of telomeres in telomerase positive and telomerase negative cells. Methods and kits for detecting pathologically proliferating cells expressing TERT and L1RT are also disclosed.

The present invention generally relates to a method for developing, generating and selecting tumor-free embryonic stem (ES)-like pluripotent cells using electroporation delivery of an inducible tumor suppressor mir-302 agent into mammalian cells. More particularly, the present invention relates to a method and composition for generating a Tet-On / Off recombinant transgene capable of expressing a manually re-designed mir-302 microRNA (miRNA) / shRNA agent under the control of doxycyclin (Dox) in human somatic / cancer cells and thus inducing certain specific gene silencing effects on the differentiation-associated genes and oncogenes of the cells, resulting in reprogramming the cells into an ES-like pluripotent state.

The present disclosure provides a method for enhancing the anti-tumor efficacy of an Fc fusion protein which binds specifically to a target, e.g., a co-inhibitory or co-stimulatory receptor of ligand, on a T cell in a subject afflicted with a cancer or a disease caused by an infectious agent and alters the activity of the immunomodulatory target, thereby potentiating an endogenous immune response against cells of the cancer or the infectious agent, wherein the method comprises selecting, designing or modifying the Fc region of the Fc fusion protein so as to enhance the binding of said Fc region to an activating Fc receptor (FcR). The disclosure also provides an Fc fusion protein produced by said method and its use in treating a subject afflicted with a cancer or a disease caused by an infectious agent.

The invention discloses a traditional Chinese medicine composition for treating all cancers, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 10-20 parts of oldenlandia diffusa, 25-30 parts of solidago virgaurea, 15-25 parts of scutellaria barbata, 5-15 parts of lobelia chinensis and 15-20 parts of spica prunellae. The traditional Chinese medicine composition is prepared from the pure Chinese herbal medicines as raw materials, contains no hormones or any additives, and solves the problem of large toxic and side effects of a conventional traditional Chinese medicine composition. The traditional Chinese medicine composition for treating all cancers has the advantages of safe and effective treatment of various cancers and little toxic and side effects, can regulate the symptoms of systemic chronic diseases of cancer. Firstly, the traditional Chinese medicine composition guarantees that the spleen and stomach of middle jiao arein harmony with qi to generate wealth, can let cancer cells enter the cancer state, withdraws occupied territories (viscera) and returns to a local area, restores the original state of the cancer cells, makes use of strengthening body resistance and eliminating evil, letting evil return to the right, communicating Yin and Yang, removing relationship of generation-inhibition in five elements, harmonizing Yin and Yang, and harmonizing Qi and blood, and solves the cancer state, so as to achieve the purposes of regulating and conditioning the environment of the cancer cells and curing cancer.

The instant invention provides methods of prognosing the ability of a zearalenone analog compound to treat a cancer in a subject, methods of prognosing the ability of a zearalenone analog compound to inhibit the growth of a cancer in a subject, and methods of prognosing the ability of a zearalenone analog compound to promote the activation of apoptosis of a cancer in a subject. Methods of treating a cancer in a subject are also provided. The invention also pertains to methods of determining whether a cancer in a subject is sensitive to treatment with a zearalenone analog compound.

This invention relates to a complex for cancer cell chemotherapy and, more particularly, to a HER2 aptamer-anticancer drug complex for chemotherapy of cancer cells, which includes a nucleic acid aptamer specifically binding to HER2 and an anticancer drug linked with the nucleic acid aptamer, so that HER2-positive breast cancer cells are selectively targeted and killed.

The invention discloses a preparation method of a folic acid self-assembled water-soluble rare-earth doped up-converted nanometer material. The preparation method mainly comprises the following steps: taking 9mL of diglycol and 6mL of high-purity water as solvents, adding 1mmol of Ln(Y / Yb / Er=80 / 18 / 2), 16mmol of NaF and 0.15g of polyethyleneimine (PEI), measuring the pH which is 9, stirring and reacting for 0.5 hour in the presence of nitrogen at 200 DEG C, transferring to a reaction kettle, reacting for 24 hours at 200 DEG C, naturally cooling and centrifugally washing to obtain polyethyleneimine modified up-converted nanometer particles (PEI-UCNPs), dispersing 1g of the PEI-UCNPs in the high-purity water, adding 0.1g of folic acid, oscillating for 15 minutes, centrifugally washing, and then dispersing in the high-purity water to obtain folic acid self-assembled up-converted nanometer particles (FA-UCNPs). As the folic acid and a folic acid receptor can be specifically bound with each other, the folic acid self-assembled rare-earth doped up-converted nanometer material can be used for identifying cancer cells and applied to targeting imaging of the cancer cells.